Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 39 of 6351
-
New CAR-T therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingFRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Robot-Guided brain zaps: a new hope for postpartum depression?
Disease control Not yet recruitingThe purpose of this study is to identify multimodal biological markers associated with postpartum depression (PPD) and to evaluate the effectiveness of precision brain stimulation treatment. PPD is a common mental health condition after childbirth that can affect maternal well-be…
Sponsor: University of Macau • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
A future without surgery for stomach and colon cancers?
Disease control Not yet recruitingThe NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy in patients with gastrointestinal cancers. Patien…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can adding immunotherapy to standard care beat a tough head and neck cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck squamous cell that are not amenable to surgery. The study…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a Two-Drug punch shrink oral tumors before surgery?
Disease control Not yet recruitingThis study is a multicenter, prospective, single-arm Phase II clinical trial evaluating the efficacy and safety of neoadjuvant therapy with TROP-2 ADC in combination with toripalimab for resectable locally advanced oral squamous cell carcinoma, followed by curative surgery and po…
Phase 2 • Sponsor: Shanghai East Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a weekly shot help chinese adults shed significant weight?
Disease control Not yet recruitingOverweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in Ch…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a drug combo replace chemo before breast cancer surgery?
Disease control Not yet recruitingThis is a single-arm, prospective, multicenter, phase II clinical study evaluating the efficacy and safety of a chemotherapy-free neoadjuvant regimen in patients with HR-positive/HER2-positive (HR+/HER2+) early or locally advanced breast cancer. Approximately 33 treatment-naive …
Phase 2 • Sponsor: Shengjing Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Three-Drug combo erase mantle cell lymphoma without chemotherapy?
Disease control Not yet recruitingThe researchers are doing this study to find out whether the combination of zanubrutinib, obinutuzumab, and sonrotoclax (BOSon) is an effective treatment approach for people with mantle cell lymphoma (MCL).
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart Hard-to-Treat gynecological cancers?
Disease control Not yet recruitingThis is a prospective, open-label, multicenter, single-arm Phase II study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT/SKB264) in combination with tagitanlimab (KL-A167) as second-line or later therapy in patients with recurrent or metastatic M…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a diabetes drug shield the heart during a heart attack procedure?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart attack. Primary PCI is a procedure that opens blocked…
Phase 2 • Sponsor: Rehman Medical Institute - RMI • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new infusion drug boost stroke recovery?
Disease control Not yet recruitingThis phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke
Phase 2 • Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
Disease control Not yet recruitingThe RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1). Participants will receive Radscopal radiotherapy, consisting of low-dose radiotherapy to the primary lesions and stereotactic body radi…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant myeloma?
Disease control Not yet recruitingThis Phase II, open-label, multicenter study will evaluate teclistamab in combination with pomalidomide administered using an alternative dosing approach in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of therapy, including lenalidom…
Phase 2 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combination targets rare childhood leukemia that resists standard treatment
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Revumenib in combination with Fludarabine and Cytarabine can treat children with NUP98-rearranged relapsed or refractory Acute Myeloid Leukemia. The main question it aims to answer is: What is the Best Overall Response Rate by morph…
Phase 2 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Phase 2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a new Add-On drug tame severe asthma Flare-Ups?
Disease control Not yet recruitingThe study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a targeted drug combo outsmart a common pancreatic cancer mutation?
Disease control Not yet recruitingThis is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy. The purpose of this study is to evaluate the anti-tumor efficacy of GF…
Phase 2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new drug outperform standard chemo for advanced breast cancer?
Disease control Not yet recruitingThis is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.
Phase 3 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug curb COPD Flare-Ups?
Disease control Not yet recruitingThe study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a pill restore calcium balance in hypoparathyroidism?
Disease control Not yet recruitingThe aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
Phase 3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC